Friday, 16 October 2026European Markets

MERCK AND CO INC And ESSILORLUXOTTICA Have A High Dividend Yield And Return On Equity In The Healthcare Sector.

Loading stream...

(vianews) - merck and co inc (mrk.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.

financial asset price forward dividend yield return on equity
merck and co inc (mrk.pa) €102.60 2.61% 29.69%
essilorluxottica (el.pa) €169.78 1.75% 6.16%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. merck and co inc (mrk.pa)

2.61% forward dividend yield and 29.69% return on equity

merck & co., inc. operates as a healthcare company worldwide. it operates through two segments, pharmaceutical and animal health. the pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. the animal health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. the company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. it has collaborations with astrazeneca plc; bayer ag; eisai co., ltd.; ridgeback biotherapeutics lp; and gilead sciences, inc. to jointly develop and commercialize long-acting treatments in hiv. merck & co., inc. was founded in 1891 and is headquartered in rahway, new jersey.

earnings per share

as for profitability, merck and co inc has a trailing twelve months eps of €4.77.

pe ratio

merck and co inc has a trailing twelve months price to earnings ratio of 21.51. meaning, the purchaser of the share is investing €21.51 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.69%.

more news about merck and co inc.

2. essilorluxottica (el.pa)

1.75% forward dividend yield and 6.16% return on equity

essilorluxottica société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in europe, middle east, africa, latin america, asia-pacific, and north america. it operates through professional solutions and direct to consumer segments. the company offers lens under the crizal, essilor, eyezen, stellest, xperio, optifog, satisloh, barberini, shamir, nikon, kodak lens, oakley, optifog, ray-ban, transitions, vailux, and xperio brands. it also provides eyewear products under the ray-ban, oakley, persol, oliver peoples, alain mikli, costa del mar, native eyewear, luxottica, sferoflex, heritage, sensaya, miki ninn, dbyd, unofficial and seen, arnette, vogue eyewear, bolon, molsion, and ossé, as well as other licensed brands. in addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. it wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. the company was formerly known as essilor international société anonyme and changed its name to essilorluxottica société anonyme in october 2018. essilorluxottica société anonyme was founded in 1849 and is headquartered in paris, france.

earnings per share

as for profitability, essilorluxottica has a trailing twelve months eps of €4.83.

pe ratio

essilorluxottica has a trailing twelve months price to earnings ratio of 35.15. meaning, the purchaser of the share is investing €35.15 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 6.16%.

volatility

essilorluxottica's last week, last month's, and last quarter's current intraday variation average was a negative 1.58%, a negative 0.37%, and a positive 1.13%.

essilorluxottica's highest amplitude of average volatility was 1.58% (last week), 0.96% (last month), and 1.13% (last quarter).

volume

today's last reported volume for essilorluxottica is 126647 which is 75.95% below its average volume of 526766.

yearly top and bottom value

essilorluxottica's stock is valued at €169.78 at 22:30 est, under its 52-week high of €188.28 and way above its 52-week low of €132.70.

moving average

essilorluxottica's value is above its 50-day moving average of €168.07 and above its 200-day moving average of €164.43.

more news about essilorluxottica.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com